10
Participants
Start Date
November 1, 2018
Primary Completion Date
February 5, 2020
Study Completion Date
February 5, 2020
PD-L1
IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
Herlev and Gentofte Hospital, Hellerup
University of Copenhagen
OTHER
Herlev and Gentofte Hospital
OTHER